HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe
Tóm tắt
Combination antiretroviral therapy (cART) may vary in ability to suppress viral load and increase CD4+ T-cell count in people infected with different HIV-1 subtypes, possibly due to differences in resistance development. Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide.
To compare virological and immunological response to cART between patients infected with B and non-B subtypes across Europe.
EuroSIDA prospective, observational cohort with 11,928 HIV-1-infected patients.
Response to cART was analysed in patients with subtypes determined pre-cART, via multivariable logistic regression on the first measurements 6–12 months after starting cART. A virological response was defined as a viral load <500 copies/ml and immunological response as a CD4+ T-cell count increase of ≥100 cells/mm3.
Forty-five percent of patients were antiretroviral naive at initiation of cART. Virological suppression was achieved by 58% of 689 subtype-B-infected patients and 66% of 102 non-B-infected patients ( P=0.159). After adjustment for potential confounders, there was no significant difference in odds of achieving virological suppression (non-B compared with B; odds ratio [OR]: 1.05, 95% confidence interval [CI]: 0.58–1.93, P=0.866). An immunological response was achieved by 43% of 753 B-infected patients and 48% of 114 non-B-infected patients ( P=0.334). After adjustment, there was no significant difference in odds of an immunological response (OR: 1.17, 95% CI: 0.73–1.87, P=0.524).
There was no evidence of significant differences in virological or immunological response to cART between patients infected with HIV-1 B and non-B subtypes.
Từ khóa
Tài liệu tham khảo
Carr J.K., 1998, Human retrovirus and AIDS 1998, a compilation and analysis of nucleic acid and amino acid sequences.
Kandathil A.J., 2005, Indian J Med Res, 121, 333
Leitner T., 1997, Human retrovirus and AIDS 1997, a compilation and analysis of nucleic acid and amino acid sequences., 19
Kantor R., 2003, AIDS Rev, 5, 25
Peeters M., 2000, Human retrovirus and AIDS 2000, a compilation and analysis of nucleic acid and amino acid sequences., 39
Robertson D.L., 1997, Human retrovirus and AIDS 1997, a compilation and analysis of nucleic acid and amino acid sequences., 25
HIV Sequence Database [homepage on Internet]. Los Alamos National Laboratory; 2005–2006 [updated 2006 May 25; cited 2006 May 4]. The circulating recombinant forms (CRFs). Available from: http://hiv-web.lanl.gov/content/hiv-db/CRFs/CRFs.html.
Loveday C., Burke A., Van Hooff F., Johnson M. Equivalence in virological responses to HAART in patients with HIV-1 subtype non-B infections: a case-controlled study (n=100). 8th Conference on Retroviruses and Opportunistic Infections. February 2001, Chicago, USA. Abstract 526.
Easterbrook P.J., Smith M., Geretti A.M., Osner N., Murad S., Oshea S. Impact of HIV-1 viral subtype on disease progression. XIVth International AIDS Conference. 7–12 July 2002, Barcelona, Spain. Abstract ThPpC2144.
Copenhagen HIV Programme [homepage on the Internet]. Denmark: Hvidovre University Hospital; 2003 [cited 2006 Aug 15]. EuroSIDA a multicentre study: Tracking HIV/AIDS across Europe 2003. Available from: http://www.cphiv.dk/EuroSIDA/Publications/TrackingHIVAIDS/tabid/156/Default.aspx.
Centers for Disease Control and Prevention, 1992, MMWR Recomm Rep, 41, 1
Johnson V.A., 2005, Top HIV Med, 13, 51